Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. As of today (2026-09-22), Eurofins Scientific SE's 10-Year Sharpe Ratio is 0.29.
Eurofins Scientific SE (OTCPK:ERFSF) 10-Year Sharpe Ratio Explanation
The 10-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past ten years. It is calculated as the annualized result of the average ten-year monthly excess returns divided by its standard deviation in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
Eurofins Scientific SE 10-Year Sharpe Ratio Related Terms
ERFSF vs TMO, DHR, NTRA: 10-Year Sharpe Ratio Comparison
For the Diagnostics & Research subindustry, Eurofins Scientific SE's 10-Year Sharpe Ratio, along with its competitors' market caps and 10-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE 10-Year Sharpe Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's 10-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's 10-Year Sharpe Ratio falls into.
Eurofins Scientific SE 10-Year Sharpe Ratio Calculation
The 10-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last ten years. A stock / portfolio's 10-Year Sharpe Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past ten years.
Eurofins Scientific SE (ERFSF) has a 10-Year Sharpe Ratio of 0.29 as of Sep. 22, 2026. 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. View historical data for Eurofins Scientific SE and its competitors.
Is Eurofins Scientific SE's 10-Year Sharpe Ratio too high?
Eurofins Scientific SE's current 10-Year Sharpe Ratio is 0.29. Overall, Eurofins Scientific SE has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's 10-Year Sharpe Ratio compare to TMO and DHR?
Eurofins Scientific SE's 10-Year Sharpe Ratio of 0.29 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Sharpe Ratio for a Medical Diagnostics & Research company?
A good 10-Year Sharpe Ratio depends on the Medical Diagnostics & Research industry context. However, 10-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Sharpe Ratio mean?
A high 10-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 10-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past ten years. View historical data for Eurofins Scientific SE and its competitors. Eurofins Scientific SE's current 10-Year Sharpe Ratio is 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (ERFSF) is currently considered Modestly Overvalued. The stock's GF Value™ is $76.18, compared to a current price of $91.95 — trading 20.7% above its estimated fair value. The current 10-Year Sharpe Ratio is 0.29. Eurofins Scientific SE's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Sharpe Ratio calculated?
10-Year Sharpe Ratio is calculated from a company's financial statements. For Eurofins Scientific SE (ERFSF), the current 10-Year Sharpe Ratio is 0.29 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (ERFSF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of $91.95 is trading 20.7% above its estimated GF Value™ of $76.18.
GuruFocus considers Eurofins Scientific SE to be Modestly Overvalued.
Key valuation signals for ERFSF:
10-Year Sharpe Ratio: 0.29
GF Value™: $76.18 vs. price of $91.95 (20.7% above fair value)
No single metric tells the full story. See the ERFSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins Scientific SE is a Luxembourg-based laboratory testing company operating a decentralized network of laboratories and service companies worldwide. It provides analytical testing and laboratory services across several segments: food, feed, and environmental testing; biopharmaceutical services, including contract research and bioanalytical testing; diagnostic services and products for clinical and medical applications; and consumer product and technology testing. Its tests assess the safety, identity, composition, authenticity, purity, origin, and traceability of biological substances and products. Customers include food producers, pharmaceutical and biotechnology companies, healthcare providers, government agencies, and consumer goods manufacturers. Eurofins operates a large network of laboratories and sites across Europe, North America, and the rest of the world, with Europe and North America representing the largest revenue regions. Revenue is generated primarily through fee-for-service testing contracts, diagnostic testing, and related laboratory services.
82GF Score
Get the complete analysis for ERFSF
10-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERFSF has been successfully added to your 
